September 2014 Edition Vol.11, Issue 9

Featured Articles

September 2014Edition

The risk of recurrence in stage II colon cancer patients is not easily predicted with traditional clinical and pathologic factors. We explore the success of the Oncotype DX® Colon Cancer Assay in improving the ability to quantify recurrence risk fo...

Key announcements from Threshold and Sunesis, pivotal data from large caps players like BMS and Roche, and a flurry of FDA approval decisions on cancer drugs are due from now until early-mid 2015. OBR reports on some upcoming clinical catalysts. ...

Anti-angiogenesis inhibitors like Avastin have changed the cancer treatment landscape for the better but they also present a number of challenges to clinicians. Not the least of these is finding reliable biomarkers to improve their clinical efficacy ...

The treatment paradigm for metastatic castrate-resistant prostate cancer (mCRPC) is rapidly changing as newer, less toxic agents are introduced for use in both chemo-naïve patients and in later settings. We dissect the shifting trends and look at al...